BiotechTube
ImmunOs Therapeutics

ImmunOs Therapeutics

Schlieren, Switzerland· Est.
immunostherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $105M

Overview

ImmunOs Therapeutics is a private, preclinical-stage biotech company leveraging a multi-modal approach to develop next-generation immunotherapies for oncology and inflammatory conditions. Founded in 2016 and headquartered in the Swiss biotech hub of Schlieren, the company is in the early stages of building its pipeline. As a typical early-stage biotech, it is pre-revenue and focused on advancing its research platform and programs toward clinical validation.

OncologyInflammatory Diseases

Technology Platform

Multi-modal immunotherapy platform targeting the immune system for cancer and inflammatory diseases, leveraging antibodies, biologics, and small molecules.

Funding History

2
Total raised:$105M
Series B$75M
Series A$30M

Opportunities

The company operates in the large and growing global markets for cancer immunotherapy and targeted treatments for inflammatory diseases.
Its multi-modal approach allows for flexibility in targeting novel immune pathways and developing best-in-class therapeutics.
Being located in Switzerland provides access to a strong biotech ecosystem, academic collaboration, and investment.

Risk Factors

Faces high scientific risk as an early-stage company with undisclosed, novel targets that may not translate to clinical efficacy or safety.
Significant financing risk depends on raising capital in a competitive environment.
Intense competition from larger, well-resourced companies in the crowded immuno-oncology and immunology spaces.

Competitive Landscape

ImmunOs competes in the highly competitive fields of immuno-oncology and immunology, dominated by large pharma and numerous biotech startups. Differentiation will require demonstrating a novel mechanism of action, superior efficacy, or improved safety profile compared to existing checkpoint inhibitors, cytokine therapies, and anti-inflammatory biologics.

More companies in Biologics / Biosimilars →More companies in Switzerland →